Plumericin 

Plumericin is an anti-inflammatory, antioxidant, and antibacterial agent. Plumericin reduces Apoptosis, promotes Nrf-2 and inhibits NF-κB and AhR activation, blocks STAT3 signaling. Plumericin inhibits Mycobacterium tuberculosis growth. Plumericin can be used for the research of chronic kidney disease, vascular diseases, inflammatory bowel diseases, peritonitis, and tuberculosis^{[1][2][3][4][5][6]}.

Plumericin (0.5-2 μM; 1 h pre-incubation, then 24 h co-incubation with IS) significantly reduces IS-induced apoptosis, decreases Bax expression, and increases Bcl-2 expression in IEC-6 cells^[1].
Plumericin (0.5-2 μM; 1 h pre-incubation, then 24 h co-incubation with IS) significantly inhibits IS-induced expression of iNOS, COX-2, and caspase-1, as well as IL-1β production, in IEC-6 cells^[1].
Plumericin (0.3-3 μM; 30 min pre-incubation, 24 h serum-stimulated) inhibits serum-induced proliferation of primary rat aortic VSMC with an IC₅₀ of 1.11 μM, as measured by BrdU incorporation following 30 min pre-incubation and 24 h serum stimulation^[2].
Plumericin (0.5-2 μM; 24 h) does not reduce proliferation of rat intestinal epithelial IEC-6 cells^[3].
Plumericin (0.3-10 μM; 30 min pretreatment + 4 h incubation) potently inhibits TNF-α-induced and constitutively active IKK-β-induced NF-κB pathway activation in HEK293/NF-κB-luc cells, with an IC₅₀ of 1.07 μM for TNF-α-induced transactivation, and does not alter basal NF-κB activity^[4].
Plumericin (0.5-2 μM; 24 h) significantly increases migration speed in LPS + IFN-stimulated IEC-6 cells, promoting intestinal epithelial wound restitution^[5].
Plumericin (serial dilutions; 5 days for MIC, 6 weeks for MBC) inhibits the growth of pan-sensitive Mycobacterium tuberculosis H37Rv with an MIC of 2.1 ± 0.12 μg/mL and reduces viable bacterial counts by ≥99% at an MBC of 3.6 ± 0.22 μg/mL^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Plumericin (3 mg/kg; i.p.; once daily; 4 days) exerts potent anti-inflammatory and antioxidant activities in male CD1 mice with DNBS (HY-W324435)-induced colitis^[3].
Plumericin (3 mg/kg; i.p.; twice) statistically significantly reduces thioglycollate-induced neutrophil recruitment to the peritoneal cavity of mice (P < 0.001)^[4].
Plumericin (3 mg/kg; i.p.; once daily; 4 days) significantly alleviates colonic inflammation, PARP activation, and apoptotic damage in DNBS-induced mouse colitis models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

290.27

C₁₅H₁₄O₆

77-16-7

C(\C)=C/1\[C@]2([C@]3([C@@]4([C@](C=C3)(C(C(OC)=O)=CO[C@@]4(O2)[H])[H])[H])OC1=O)[H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rispoli RM, et al. Plumericin Modulates the AhR-NFκB-Nrf2 Signaling Network to Counteract Indoxyl Sulfate-Induced Intestinal Epithelial Cells Impairment. Int J Mol Sci. 2025;27(1):293. Published 2025 Dec 27.  [Content Brief]

  [2]. Heiss EH, et al. Plumericin inhibits proliferation of vascular smooth muscle cells by blocking STAT3 signaling via S-glutathionylation. Sci Rep. 2016;6:20771. Published 2016 Feb 9.  [Content Brief]

  [3]. Rapa SF, et al. Plumericin prevents intestinal inflammation and oxidative stress in vitro and in vivo. FASEB J. 2020;34(1):1576-1590.  [Content Brief]

  [4]. Fakhrudin N, et al. Identification of plumericin as a potent new inhibitor of the NF-κB pathway with anti-inflammatory activity in vitro and in vivo. Br J Pharmacol. 2014;171(7):1676-1686.  [Content Brief]

  [5]. Rapa SF, et al. Plumericin Protects against Experimental Inflammatory Bowel Disease by Restoring Intestinal Barrier Function and Reducing Apoptosis. Biomedicines. 2021;9(1):67. Published 2021 Jan 12.  [Content Brief]

  [6]. Kumar P, et al. Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis. Pulm Pharmacol Ther. 2013;26(3):332-335.  [Content Brief]